Hypertriglyceridemia: Difference between revisions
imported>Robert Badgett m (→Treatment) |
imported>Robert Badgett |
||
| Line 10: | Line 10: | ||
Regarding treatment, the AIM-HIGH found that niacin did not reduce the risk of cardiovascular events.<ref>{{cite web |url= http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2792 |title=NHLBI - Press Release |author=Anonymous |work=public.nhlbi.nih.gov |year=2011 [last update] |accessdate=July 26, 2011}}</ref> | Regarding treatment, the AIM-HIGH found that niacin did not reduce the risk of cardiovascular events.<ref>{{cite web |url= http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2792 |title=NHLBI - Press Release |author=Anonymous |work=public.nhlbi.nih.gov |year=2011 [last update] |accessdate=July 26, 2011}}</ref> | ||
Regarding treating triglycerides among patients exclusively with [[diabetes mellitus]] with levels less than 650 mg/dl, "the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone" according to | Regarding treating triglycerides among patients exclusively with [[diabetes mellitus]] with levels less than 650 mg/dl, "the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone" according to the ACCORD [[randomized controlled trial]]. <ref name="pmid20228404">{{cite journal| author=ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA et al.| title=Effects of combination lipid therapy in type 2 diabetes mellitus. | journal=N Engl J Med | year= 2010 | volume= 362 | issue= 17 | pages= 1563-74 | pmid=20228404 | url=http://www.nejm.org/doi/full/10.1056/NEJMoa1001282}}</ref> However, among the diabetics with [[triglyceride]]s about 204 and [[HDL cholesterol]] less than 34, there was significant better (primary outcome over 5 years reduced from 17% to 12%).<ref name="pmid20228404"/> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 02:52, 6 June 2012
In medicine hypertriglyceridemia is a dyslipidemia and is "a condition of elevated levels of triglycerides in the blood".[1]
One cause is hypoalphalipoproteinemia.
Treatment
Clinical practice guidelines state:[2] "Patients in whom triglycerides >500 mg/dL should receive strict diet therapy including avoidance of alcohol, restriction of dietary fat, and avoidance of concentrated carbohydrates (sweets). For triglycerides >1000 mg/dL a very low fat diet should be instituted quickly to reduce chylomicronemia and risk of acute pancreatitis"
Regarding treatment, the AIM-HIGH found that niacin did not reduce the risk of cardiovascular events.[3]
Regarding treating triglycerides among patients exclusively with diabetes mellitus with levels less than 650 mg/dl, "the combination of fenofibrate and simvastatin did not reduce the rate of fatal cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with simvastatin alone" according to the ACCORD randomized controlled trial. [4] However, among the diabetics with triglycerides about 204 and HDL cholesterol less than 34, there was significant better (primary outcome over 5 years reduced from 17% to 12%).[4]
References
- ↑ Anonymous (2024), Hypertriglyceridemia (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ [Management of Dyslipidemia Working Group. VA/DoD clinical practice guideline for the management of dyslipidemia. Washington (DC): Department of Veterans Affairs, Department of Defense; 2006. 140 p.
- ↑ Anonymous (2011 [last update]). NHLBI - Press Release. public.nhlbi.nih.gov. Retrieved on July 26, 2011.
- ↑ 4.0 4.1 ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA et al. (2010). "Effects of combination lipid therapy in type 2 diabetes mellitus.". N Engl J Med 362 (17): 1563-74. PMID 20228404.